Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, January 16th.
Several other equities analysts also recently weighed in on the company. Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. JPMorgan Chase & Co. restated a “buy” rating and set a $76.00 price target on shares of Ultragenyx Pharmaceutical in a report on Sunday, November 5th. Robert W. Baird reduced their price target on Ultragenyx Pharmaceutical from $85.00 to $80.00 and set an “outperform” rating for the company in a report on Friday, November 3rd. Cowen restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 15th. Finally, Jefferies Group upgraded Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and raised their price target for the company from $58.00 to $72.00 in a report on Monday, December 4th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $72.06.
Ultragenyx Pharmaceutical (NASDAQ RARE) traded up $4.75 on Tuesday, reaching $58.14. The company’s stock had a trading volume of 1,638,554 shares, compared to its average volume of 554,307. The company has a market capitalization of $2,480.00, a P/E ratio of -8.34 and a beta of 1.83. Ultragenyx Pharmaceutical has a twelve month low of $43.14 and a twelve month high of $91.35.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.87). The firm had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.02 million. During the same quarter last year, the company posted ($1.64) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was up 81.8% compared to the same quarter last year. sell-side analysts anticipate that Ultragenyx Pharmaceutical will post -7.31 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new position in Ultragenyx Pharmaceutical in the third quarter worth about $156,000. Kazazian Asset Management LLC purchased a new position in Ultragenyx Pharmaceutical in the second quarter worth about $213,000. Fox Run Management L.L.C. purchased a new position in Ultragenyx Pharmaceutical in the third quarter worth about $213,000. Ameritas Investment Partners Inc. boosted its position in Ultragenyx Pharmaceutical by 7.7% in the second quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 248 shares during the last quarter. Finally, Amalgamated Bank boosted its position in Ultragenyx Pharmaceutical by 7.6% in the second quarter. Amalgamated Bank now owns 4,980 shares of the biopharmaceutical company’s stock worth $309,000 after purchasing an additional 352 shares during the last quarter. 94.10% of the stock is currently owned by institutional investors and hedge funds.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.